The Scientific Transformation of Toxicology and Drug Development: A Comprehensive Analysis of Validated Discoveries via New Approach Methodologies

The paradigm of biomedical research is currently undergoing a foundational shift, moving away from a century-long reliance on animal models toward a more human-centric framework defined by New Approach Methodologies (NAMs). These methodologies encompass a diverse suite of in $vitro$, in $silico$, and in $chemico$ technologies designed to assess chemical safety and drug efficacy with greater predictive accuracy than traditional in $vivo$ studies.[1] For decades, the pharmaceutical industry has contended with a systemic "translational gap," particularly evident in oncology, where over 90% of candidates successful in animal trials fail to achieve clinical approval due to unforeseen toxicities or lack of efficacy in humans.[3] NAMs address this gap by focusing on the fundamental biomolecular interactions and Adverse Outcome Pathways (AOPs) that drive human pathophysiology, rather than observing apical symptoms in non-human species.[5]

Conceptual Framework and Regulatory Genesis

The formalization of New Approach Methodologies as a regulatory and scientific category occurred around 2016, although many of the constituent technologies had been in development for years.[6] At its core, the NAM movement is a response to the scientific limitations of mammalian toxicity testing, which often utilizes high-dose exposures that do not accurately reflect the long-term, low-concentration exposures characteristic of real-world human environments.[5] Unlike traditional methods that prioritize outward symptoms of harm, NAMs utilize measurement tools that quantify gene products, metabolites, and cellular interactions to identify "tipping points" in biological function before clinical symptoms manifest.[5]

This transition is supported by a robust international regulatory architecture. In the United States, the FDA Modernization Act 2.0 and subsequent roadmaps published by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have established clear pathways for integrating NAM-derived data into Investigational New Drug (IND) applications.[9] The March 2026 draft guidance from the FDA's Center for Drug Evaluation and Research (CDER) provides a validation framework for these methodologies, emphasizing scientific confidence, human biological relevance, and "fit-for-purpose" utility.[11] This shift is not merely ethical but is driven by the need for improved efficiency, as NAMs offer faster and less

expensive means of gathering large volumes of data compared to lengthy and resource-intensive animal studies.[5]

Regulatory Milestone	Agency/Body	Scientific and Policy Impact
FDA Modernization Act 2.0	U.S. Congress/FDA	Removed the mandatory requirement for animal testing in preclinical drug development.[3]
NAM Validation Guidance (March 2026)	FDA CDER	Established technical characterization and "Context of Use" (COU) requirements for NAM submissions.[11]
Animal Testing Reduction Roadmap	FDA/NIH	Outlined a stepwise strategy to prioritize human-based research, starting with monoclonal antibodies.[10]
Chemicals Strategy for Sustainability	European Union	Banned endocrine-disrupting chemicals from consumer products based on NAM-driven hazard identification.[7]
OECD Guidance Document 34	OECD	Established international standards for the validation and acceptance of alternative test methods.[16]

Validated Milestones in Personalized Medicine and Rare Diseases

Perhaps the most compelling evidence of NAM-driven progress is found in the field of personalized medicine. Patient-derived organoids (PDOs) have moved beyond theoretical models to become functional "avatars" that predict individual responses to therapeutic interventions, particularly for rare genetic disorders where traditional clinical trials are unfeasible.[13]

The Utrecht Breakthrough in Cystic Fibrosis

The development of the Forskolin-induced Swelling (FIS) assay using patient-derived intestinal organoids represents a landmark success story in pharmacology.[13] Researchers at institutions like UMC Utrecht identified that the $CFTR$ channel, which is defective in Cystic Fibrosis (CF), regulates ion and water exchange within the lumen of intestinal organoids.[19] In healthy organoids, the addition of forskolin triggers swelling as water enters the hollow spheres; in CF

patient-derived organoids, this swelling is significantly reduced or absent.[13]
This discovery led to a rapid, in $vitro$ diagnostic tool to test the efficacy of $CFTR$-modulator drugs. By measuring the degree of organoid swelling, clinicians can accurately predict clinical trial responses for individual patients, including those with rare genotypes that are underrepresented in standard clinical populations.[13] This methodology has already identified successful treatments for patients with life-threatening versions of CF, allowing for tailored therapeutic strategies that have significantly increased life expectancy.[19]
The FIS assay stands as a definitive example of how NAMs can replace larger clinical cohorts with high-resolution, patient-specific biological data.

Gene Therapy and Rare Genetic Screening

The application of NAMs extends to the screening of personalized gene therapies, notably in the context of Duchenne Muscular Dystrophy (DMD). DMD is characterized by mutations in the DMD gene, leading to progressive muscle degeneration and lethal cardiac complications.[20] Traditional research relied heavily on mouse models that often failed to replicate the specific structural deletions found in human patients.
A breakthrough study utilized a streamlined workflow to convert cryopreserved peripheral blood mononuclear cells (PBMCs) into induced pluripotent stem cells (iPSCs) and subsequently into cardiac organoids within just three weeks.[20] This rapid platform enabled the screening of antisense oligonucleotides (ASOs) tailored to correct the unique splicing defects of individual patients. The research discovered that these custom ASOs could restore dystrophin expression and improve calcium transients in the cardiac microenvironment.[20] This validates the use of patient-specific organoids as a scalable, cost-effective alternative to animal models for developing both standardized and personalized gene therapies.

Oncology: Navigating Tumor Heterogeneity and Radioresistance

In oncology, the high failure rate of drug candidates is often attributed to the inability of animal models to replicate the intricate architecture, clonal diversity, and immune interactions of human tumors.[3] NAM-based approaches, specifically PDOs and organ-on-a-chip systems, offer a solution by preserving the genetic and phenotypic characteristics of the original tumor.[18]

The OPTIC Trial and Metastatic Colorectal Cancer

The OPTIC trial serves as a multicenter prospective study that validated the predictive power of PDOs in metastatic colorectal cancer (mCRC).[22] The analysis demonstrated that the response of a patient's organoids in $vitro$ correlates significantly with both radiological tumor response and clinical survival outcomes, particularly for oxaliplatin-based chemotherapy.[22] This discovery highlights the value of NAMs in identifying ineffective therapies early, thereby minimizing patient exposure to toxicity and optimizing treatment selection.

Further research using PDOs has elucidated the molecular determinants of radioresistance. By modeling mechanisms such as enhanced DNA damage repair, hypoxia-driven metabolic reprogramming, and radiation-induced senescence, researchers can now identify actionable pathways that make radiotherapy more effective.[23] Integrating these models with vascular and immune components allows for the concurrent assessment of normal tissue toxicity, a critical step in defining the therapeutic window for new radiosensitizers.[23]

Immune Microenvironment and Cancer Vaccines

The development of organoid immune co-culture models has revolutionized the study of immunotherapies. By co-culturing tumor organoids with autologous peripheral blood lymphocytes, researchers can simulate the tumor immune microenvironment (TIME) to assess individual responses to checkpoint inhibitors and CAR-T cell therapies.[18] This has enabled the identification of tumor-specific antigens with high immunogenicity, providing a breakthrough platform for the design of personalized cancer vaccines.[18] Unlike traditional 2D cultures, these 3D systems capture the spatial organization and immune dynamics necessary to predict how a patient's immune system will react to a specific treatment.[21]

Oncology Platform	Key Mechanism Studied	Validated Outcome/Discovery
Gastrointestinal PDOs	Response to 5-FU/Irinotecan	83.3% accuracy in predicting patient survival and tumor response.[25]
Metastatic mCRC Organoids	Oxaliplatin sensitivity	Identification of radiological response correlation in the OPTIC trial.[22]
Immune-Co-culture Models	CAR-T cell interaction	Direct linkage between lab findings and patient survival outcomes.[18]
Radio-sensitization Models	DNA damage repair pathways	Identification of hypoxia-driven metabolic resistance mechanisms.[23]

The Toxicological Revolution: Tox21 and High-Throughput Screening

The shift toward NAMs is perhaps most evident in the assessment of environmental and industrial chemicals through the Tox21 consortium. This federal collaboration utilizes robotic high-throughput screening (HTS) to evaluate thousands of chemicals simultaneously, generating millions of data points on biological pathways.[26]

Endocrine Disruption and the Estrogen Receptor Model

A major success of the Tox21 initiative is the development of an 18-assay battery for the estrogen receptor (ER) pathway.[26] This battery uses robot-based results to identify compounds that interfere with human hormones, a process that traditionally required the use of thousands of laboratory animals.[26] The EPA has formally accepted this computational model as an alternative to certain Tier 1 screening assays, such as the rodent uterotrophic assay.[28] This marks the first time a regulatory agency has prioritized robotically derived molecular data over traditional animal testing for hazard identification.

Advanced Risk Assessment and Points of Departure

NAMs have introduced the concept of the "point of toxicological departure" (PoD) based on molecular initiating events.[5] In data-poor situations, such as the assessment of emerging PFAS compounds, the Government of Canada and the U.S. EPA utilize in $vitro$ assays to calculate human equivalent doses (HED).[31] By comparing this HED to human exposure estimates, researchers can derive a Bioactivity-Exposure Ratio (BER), which serves as a protective surrogate in the absence of traditional animal data.[31] This risk-based approach ensures that chemicals are prioritized for further action based on their actual likelihood of biological perturbation in humans, rather than arbitrary safety factors applied to animal data.

Organ-on-a-Chip and Microphysiological Systems: Functional Milestones

The emergence of Microphysiological Systems (MPS), or Organs-on-a-Chip, has provided insights into organ-level toxicity that animal models frequently miss due to species-specific metabolic differences.

Drug-Induced Liver Injury (DILI)

The Emulate liver-on-a-chip model is a frequently cited success, correctly identifying hepatotoxicity in 87% of drugs that had previously tested as safe in animal models but were later found to be toxic in humans.[32] This discovery highlights the platform’s ability to recapitulate human-specific metabolic dynamics, including the secretion of albumin and the activation of mechanical stimuli within the extracellular matrix.[33]

Kidney Assembloids and Fibrosis Modeling

Researchers have recently described the generation of the most complex kidney structures to date—assembloids that combine filtering nephrons with urine-concentrating collecting ducts.[35] These models achieve a level of maturity equivalent to a newborn human kidney, expressing critical transporters such as SGLT2 and organic anion/cation transporters.[35] For the first time, these assembloids have recapitulated key features of polycystic kidney disease (PKD), including inflammation and fibrosis, disease hallmarks that were previously irreproducible in traditional models.[35] This discovery opens new doors for studying the pathogenic progression of chronic kidney disease and for the accurate prediction of drug-induced nephrotoxicity.

Artificial Intelligence and Computational Discoveries

The integration of Artificial Intelligence (AI) and Machine Learning (ML) with NAMs has accelerated the discovery of novel therapeutic candidates and the repurposing of existing drugs.

Drug Repurposing Success Stories

Computational NAMs utilize transcriptomic reversal scoring and network pharmacology to identify new uses for approved medications.[36] Specific success stories identified through these methods include:

- **Inflammatory Bowel Disease (IBD):** The drug topiramate was identified as a candidate for IBD through transcriptomic analysis, which predicted its ability to reverse disease-specific expression profiles.[36]
- **COVID-19 Therapeutics:** High-throughput screening (HTS) identified existing compounds capable of inhibiting the TMPRSS2 protease, a critical mechanism for SARS-CoV-2 viral entry.[36]
- **Neurodegenerative Disorders:** HTS methodologies pinpointed compounds capable of disrupting 14-3-3 protein interactions, offering potential treatments for conditions like Amyotrophic Lateral Sclerosis (ALS).[13]

Genomic Syntax and Natural Product Discovery

In the realm of synthetic biology, the CoreFinder system utilizes transformer-based models to predict biosynthetic gene cluster (BGC) functions.[37] This system discovered novel BGCs in fungi that were previously unannotated, a finding validated through in $vitro$ fermentation and LC-MS analysis.[37] Such AI-driven NAMs are unlocking new biosynthetic pathways for pharmaceutical advancement, demonstrating that computational approaches can drive valid scientific discoveries independently of traditional experimental paradigms.

The Cosmetics Industry: A Paradigm for Complete Replacement

The regulatory landscape for cosmetics, particularly in the European Union, has mandated the development of animal-free alternatives for safety testing.[38] This has led to the validation and international acceptance of several NAM-based test guidelines by the OECD.[17]

Skin Sensitization and Eye Irritation

The transition from the murine Local Lymph Node Assay (LLNA) to in $chemico$ and in $vitro$ batteries for skin sensitization is a major achievement.[16] Test guidelines such as OECD TG 442C investigate covalent protein binding—the molecular initiating event of skin allergy—without the use of animal or human cells.[16] For eye irritation, Defined Approaches (DAs) now integrate multiple in $vitro$ methods, such as the Bovine Corneal Opacity and

Permeability (BCOP) test and the Reconstructed Human Epidermis (RHE) test, to identify serious eye damage without reliance on the Draize rabbit eye test.[16]

NAM Assay	Target Endpoint	Associated OECD Guideline
BCOP Test	Ocular Corrosivity/Irritation	OECD TG 437.[16]
In Chemico Sensitization	Covalent protein binding	OECD TG 442C.[16]
RHE Test	Skin Corrosion/Irritation	OECD TG 431 / 439.[16]
3T3 NRU Test	Phototoxicity	OECD TG 432.[16]
Caco-2 Cell Assay	Oral Absorption	Standard in $vitro$ screening.[38]

Model-Informed Drug Development (MIDD) and PBPK Modeling

The integration of NAM data into computational models has enabled Model-Informed Drug Development (MIDD), which optimizes the quantitative risk estimates associated with new therapies.[41]

Physiologically Based ToxicoKinetics (PBTK)

PBTK (and PBPK) models integrate in $vitro$ data regarding absorption, distribution, metabolism, and excretion (ADME) with physiological parameters to predict internal human exposure.[41] This approach has been used to assess the safety of cosmetic ingredients based solely on NAM-derived data, quantifying the "margin of safety" needed to cover uncertainties in extrapolation.[43] For instance, a framework using PBPK models correctly estimated the systemic exposure of caffeine and coumarin in different product types, demonstrating that model-informed approaches can replace in $vivo$ toxicokinetics in certain contexts.[43]

Quantitative Systems Pharmacology (QSP)

QSP models represent an advanced frontier in NAMs, combining mechanical simulations of physiology with molecular signaling pathways.[34] The FDA has highlighted QSP as a tool that can reduce reliance on animal testing by providing a virtual platform to test "what-if" scenarios for complex biologics.[34] This is particularly relevant for monoclonal antibodies (mAbs), where QSP models can predict immunogenicity and pharmacokinetics by learning patterns from molecules that previously caused adverse events in patients.[34]

Future Trajectories and Challenges in NAM Adoption

While the validation of NAMs has led to significant scientific discoveries, several barriers remain to their universal implementation. Technical challenges include the lack of systemic integration in some in $vitro$ models, limited duration of exposure, and the need for standardized protocols to ensure inter-laboratory reproducibility.[3] Furthermore, there is a cultural and

societal inertia among researchers and regulators who are familiar with established animal methods.[46]

However, the trajectory is clear. The ongoing development of "digital twins"—virtual representations of individuals integrating clinical, genetic, and environmental data—promises to revolutionize clinical trial design by simulating treatment strategies before patient enrollment.[32] As stem cell technology matures, the ability to generate multi-zonal organoids that capture the functional zonation of the human liver or heart will further enhance the fidelity of in $vitro$ predictions.[48]

The synthesis of these discoveries confirms that NAMs are more than mere replacements for animal tests; they represent a fundamental transformation in scientific understanding. By leveraging the power of human biology, robotics, and artificial intelligence, NAMs are providing a faster, more accurate, and ethical pathway to protecting public health and advancing the next generation of life-saving medicines.[6] The shift toward 21st-century toxicology is no longer a prospect but a validated reality, marked by a growing list of milestones that span the entire spectrum of biomedical and chemical research.

Works cited

1. accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10964841/#:~:text=New%20approach%20methodologies%20(NAMs)%20can%20be%20defined%20as%20any%20in,to%20the%20replacement%20of%20animals.
2. New Approach Methodologies: What Clinical Pharmacologists Should Prepare For - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12404678/
3. Integrating New Approach Methodologies (NAMs) into Preclinical ..., accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12730968/
4. Are New Approach Methodologies (NAMs) the Holy Grail of toxicology? - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12790340/
5. New Approach Methodologies (NAMs) - British Toxicology Society, accessed March 24, 2026, https://www.thebts.org/wp-content/uploads/2024/05/New-approach-methodologies.pdf
6. New Approach Methodologies (NAMs): The Future of Toxicology ..., accessed March 24, 2026, https://emulatebio.com/new-approach-methodologies-nams-the-future-of-toxicology-and-safety-testing/
7. Read "New Approach Methods (NAMs) for Human Health Risk Assessment: Proceedings of a Workshop—in Brief" at NAP.edu, accessed March 24, 2026, https://www.nationalacademies.org/read/26496
8. CDER/Office of New Drugs Streamlined Nonclinical Studies and Acceptable New Approach Methodologies (NAMs) | FDA, accessed March 24, 2026, https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cderoffice-new-drugs-streamlined-nonclinical-studies-and-acceptable-new-approac

h-methodologies-nams
9. New Approach Methodologies (NAMs) in Drug Development - Biotech at Scale, accessed March 24, 2026, https://www.thermofisher.com/blog/biotechnology/new-approach-methodologies-nams-in-drug-development/
10. FDA and NIH Announce Initiatives to Reduce Animal Testing and Encourage Alternative Methodologies - Latham & Watkins, accessed March 24, 2026, https://www.lw.com/en/insights/fda-and-nih-announce-initiatives-to-reduce-animal-testing-and-encourage-alternative-methodologies
11. FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development, accessed March 24, 2026, https://www.fda.gov/news-events/press-announcements/fda-releases-draft-guidance-alternatives-animal-testing-drug-development
12. General Considerations for the Use of New Approach Methodologies in Drug Development, accessed March 24, 2026, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-use-new-approach-methodologies-drug-development
13. New Approach Methodologies Facilitating Drug Discovery ..., accessed March 24, 2026, https://www.biotechniques.com/drug-discovery-development/if-sart-nams-an-exciting-era-for-drug-discovery_sartorius/
14. The FDA's Plan to Phase Out Animal Testing - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12834477/
15. General Considerations for the Use of New Approach Methodologies in Drug Development; Draft Guidance for Industry; Availability - Federal Register, accessed March 24, 2026, https://www.federalregister.gov/documents/2026/03/19/2026-05390/general-considerations-for-the-use-of-new-approach-methodologies-in-drug-development-draft-guidance
16. 1 List of Alternative Test Methods and Strategies (or New Approach Methodologies [NAMs]) First Update - EPA, accessed March 24, 2026, https://www.epa.gov/sites/default/files/2019-12/documents/alternative_testing_nams_list_first_update_final.pdf
17. Guidelines for the Testing of Chemicals - OECD, accessed March 24, 2026, https://www.oecd.org/en/topics/sub-issues/testing-of-chemicals/test-guidelines.html
18. From petri dish to patient care: organoids bring personalised cancer therapy closer, accessed March 24, 2026, https://ecancer.org/en/news/27088-from-petri-dish-to-patient-care-organoids-bring-personalised-cancer-therapy-closer
19. Towards diagnostic and personalized models using organoids - Research at UMC Utrecht, accessed March 24, 2026, https://research.umcutrecht.nl/stories/towards-diagnostic-and-personalized-models-using-organoids/
20. Patient-Derived Organoids for Gene Therapy Development: A Breakthrough in

Precision Medicine - MarinBio, accessed March 24, 2026, https://www.marinbio.com/patient-derived-organoids-for-gene-therapy-development-a-breakthrough-in-precision-medicine/
21. Organoid models in oncology: advancing precision cancer therapy and vaccine development, accessed March 24, 2026, https://www.cancerbiomed.org/content/22/8/903
22. Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer, accessed March 24, 2026, https://aacrjournals.org/clincancerres/article/31/23/5015/767465/Patient-Derived-Organoids-Predict-Treatment
23. Patient-Derived Organoids as a Platform to Decipher and Overcome Radioresistance: From the Tumor Microenvironment to Radiosensitizer Discovery - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12731805/
24. Tiny models, powerful insights: how organoids are driving precision oncology, accessed March 24, 2026, https://www.drugtargetreview.com/news/188702/tiny-models-powerful-insights-how-organoids-are-driving-precision-oncology/
25. Promises and Challenges of Organoid-Guided Precision Medicine - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8492003/
26. Tox21: Chemical testing in the 21st century - NIEHS, accessed March 24, 2026, https://www.niehs.nih.gov/sites/default/files/health/assets/docs_p_z/tox21_understanding_the_potential_health_risks_of_chemicals_508.pdf
27. UNITED STATES FEDERAL GOVERNMENT TOX21 COLLABORATION, accessed March 24, 2026, https://tox21.gov/wp-content/uploads/2024/02/Tox21_FactSheet_Jan2023.pdf
28. About Tox21, accessed March 24, 2026, https://tox21.gov/overview/about-tox21/
29. Availability of New Approach Methodologies in the Endocrine Disruptor Screening Program; Notice of Availability and Opportunity for Comment - Federal Register, accessed March 24, 2026, https://www.federalregister.gov/documents/2023/01/19/2023-00940/availability-of-new-approach-methodologies-in-the-endocrine-disruptor-screening-program-notice-of
30. The Use of NAMs in Decision-Making - EPA Report on Statutory and ..., accessed March 24, 2026, https://www.ncbi.nlm.nih.gov/books/NBK614850/
31. Use of new approach methods (NAMs) in risk assessment - Canada.ca, accessed March 24, 2026, https://www.canada.ca/en/health-canada/services/chemical-substances/fact-sheets/use-new-approach-methods-risk-assessment.html
32. What are NAMs? - Science Advancement and Outreach Division, accessed March 24, 2026, https://www.scienceadvancement.org/reflections/what-are-nams/
33. Tumor organoids for cancer research and personalized medicine - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8958892/
34. FDA animal testing phaseout urges AI-based trial alternatives, organoids, other “NAMs”, accessed March 24, 2026,

https://www.hoganlovells.com/en/publications/fda-animal-testing-phaseout-urges-aibased-trial-alternatives-organoids-other-nams
35. Researchers develop most advanced kidney organoid yet for disease modeling and drug discovery, accessed March 24, 2026, https://www.drugdiscoverynews.com/researchers-develop-most-advanced-kidney-organic-yet-for-disease-modeling-and-drug-discovery-16677
36. From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12535746/
37. Deciphering Biosynthetic Gene Clusters with a Context-aware Protein Language Model, accessed March 24, 2026, https://www.biorxiv.org/content/10.1101/2025.04.29.651206v1.full-text
38. The Use of NAMs in Regulatory Assessments of Cosmetics Safety - NC3Rs, accessed March 24, 2026, https://nc3rs.org.uk/sites/default/files/2022-03/2022%20NAMs%20Workshop%20-%20Qasim%20Chaudhry%20slides.pdf
39. Safe Cosmetic Testing Methods Without Animals - Bibra Toxicology Advice and Consulting, accessed March 24, 2026, https://www.bibra-information.co.uk/blog/safe-cosmetic-testing-methods-without-animals
40. Chapter: 5 Issues in Developing a Scientific Confidence Framework for NAMs, accessed March 24, 2026, https://www.nationalacademies.org/read/26906/chapter/7
41. Advancing drug development with “Fit-for-Purpose” modeling informed approaches - PMC, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12436579/
42. SCCS Notes of guidance for the testing of cosmetic ingredients and their safety evaluation - 12th revision - Public Health - European Commission, accessed March 24, 2026, https://health.ec.europa.eu/publications/sccs-notes-guidance-testing-cosmetic-ingredients-and-their-safety-evaluation-12th-revision_en
43. The margin of internal exposure (MOIE) concept for dermal risk assessment based on oral toxicity data - A case study with caffeine | Request PDF - ResearchGate, accessed March 24, 2026, https://www.researchgate.net/publication/314653854_The_margin_of_internal_exposure_MOIE_concept_for_dermal_risk_assessment_based_on_oral_toxicity_data_-_A_case_study_with_caffeine
44. AI-Enabled Reduction of Animal Use in Cardiovascular Translational Medicine: Regulatory and Technological Perspectives - MDPI, accessed March 24, 2026, https://www.mdpi.com/2075-1729/15/12/1916
45. The US Federal Tox21 Program: A Strategic and Operational Plan for Continued Leadership, accessed March 24, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6664816/
46. New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption - PMC, accessed March 24, 2026,

https://pmc.ncbi.nlm.nih.gov/articles/PMC10964841/
47. From Algorithm to Medicine: AI in the Discovery and Development of New Drugs - MDPI, accessed March 24, 2026, https://www.mdpi.com/2673-2688/7/1/26
48. 10 Key Studies on Liver Research with NAMs - 2024/2025 - Cherry Biotech, accessed March 24, 2026, https://www.cherrybiotech.com/scientific-note/top-10-breakthrough-studies-using-liver-organoids-and-liver-on-chip-for-drug-discovery-2024-2025/
49. Catalyzing Research with Novel Alternative Methods - NIH Office of Science Policy, accessed March 24, 2026, https://osp.od.nih.gov/catalyzing-research-with-novel-alternative-methods/
50. Progress in New Approach Methodologies (NAMs) and the human relevant way forward in drug development, accessed March 24, 2026, https://www.humanrelevantscience.org/progress-in-new-approach-methodologies-nams-and-the-human-relevant-way-forward-in-drug-development/